Fig. 8: Biosafety analyses of ultrasmall Au1Pd3-FA nanozymes.
From: Ultrasmall metal alloy nanozymes mimicking neutrophil enzymatic cascades for tumor catalytic therapy
Effect of (a) Au1Pd3 nanozymes and (b) Au1Pd3-FA nanozymes on the cell viability of CT26 and AML12 cells (n = 3 independent experiments). P values are determined with two-way ANOVA Sidak’s multiple comparisons test. c Illustration of the renal clearance ability and tumor-specific killing effect. Graphical content was created with BioRender.com. d Body weight changes in mice 7 days and h 28 days after the treatment with Au1Pd3-FA nanozymes and PBS, respectively (n = 3 mice per group). e Routine blood tests of mice at 7 days and (i) 28 days post-injection of Au1Pd3-FA nanozymes and PBS, respectively (n = 3 mice per group). f Biomarkers of liver and kidney function analyses of mice at 7 days and (j) 28 days post-injection of Au1Pd3-FA nanozymes and PBS, respectively (n = 3 mice per group). g HE staining images of the tissue sections of heart, liver, spleen, lung, kidney, and brain obtained from mice after treatment with Au1Pd3-FA nanozymes and PBS at 7 days and (k) 28 days post-injection. Scale bar = 100 μm. All data are presented as mean ± STD. Source data are provided as a Source Data file.
